Literature DB >> 15618765

[The results of open reduction through a medial approach for developmental dysplasia of the hip in children above 18 months of age].

Muhittin Sener1, Celal Baki, Hafiz Aydin, Mehmet Yildiz, Sertaç Saruhan.   

Abstract

OBJECTIVES: Open reduction through a medial approach for the treatment of developmental dysplasia of the hip has been advocated in children younger than 18 months of age. In this study, we evaluated the results of this technique in children above 18 months of age.
METHODS: A retrospective evaluation of 34 hips (22 patients; 16 girls, 6 boys) was made, whose treatment was performed using open reduction through a medial approach between 1987 and 1997. Only typical dislocations were included. The ages of the patients at the time of surgery were either 18 months or above (mean age 23.7 months; range 18 to 54 months). Clinical and radiographic evaluations were made according to the modified McKay and Severin's criteria, respectively. The hips in which avascular necrosis developed were evaluated according to the Bucholz-Ogden classification. The mean follow-up was 10 years (range 5 to 14 years).
RESULTS: Secondary interventions were required in 24 hips (70.6%). Avascular necrosis developed in nine hips (26.5%). Final clinical results, together with secondary procedures, were excellent in 18 hips (52.9%), good in 10 hips (29.4%), moderate in four hips (11.8%), and poor in two hips (5.9%). Radiographically, there were six hips in Severin class I (17.7%), 11 hips (32.4%) in class II, 10 hips (29.4%) in class III, six hips (17.7%) in class IV, and one hip (2.9%) in class V.
CONCLUSION: These data show that, because of high rates of secondary interventions and ensuing avascular necrosis, open reduction through a medial approach cannot be considered to be successful for the treatment of developmental dysplasia of the hip in children above 18 months of age.

Entities:  

Mesh:

Year:  2004        PMID: 15618765

Source DB:  PubMed          Journal:  Acta Orthop Traumatol Turc        ISSN: 1017-995X            Impact factor:   1.511


  7 in total

1.  Letter to the Editor: Developmental Dislocation of the Hip Successfully Treated by Preoperative Traction and Medial Open Reduction: A 22-year Mean Followup.

Authors:  Atilla Citlak; Muhittin Sener
Journal:  Clin Orthop Relat Res       Date:  2015-06-13       Impact factor: 4.176

2.  Reply to the Letter to the Editor: Developmental Dislocation of the Hip Successfully Treated by Preoperative Traction and Medial Open Reduction: A 22-year Mean Followup.

Authors:  P Farsetti; R Caterini; V Potenza; E Ippolito
Journal:  Clin Orthop Relat Res       Date:  2015-07-03       Impact factor: 4.176

3.  Long-term results after two-stage operative treatment of late developmental displacement of the hip.

Authors:  Edgar Remmel; Annemarie Schraml; Kerstin Stauner; Alexander Schuh
Journal:  Int Orthop       Date:  2008-08-12       Impact factor: 3.075

4.  Treatment of Tönnis type II hip dysplasia with or without open reduction in children older than 18 months: a preliminary report.

Authors:  Budak Akman; Korhan Ozkan; Hakan Cift; Kaya Akan; Engin Eceviz; Abdullah Eren
Journal:  J Child Orthop       Date:  2009-07-29       Impact factor: 1.548

5.  The path to minimizing instability in developmental dysplasia of the hip: is Capsulorrhaphy a necessity or a futile habit?

Authors:  Ramin Zargarbashi; Mohammadreza Bozorgmanesh; Behnam Panjavi; Fardis Vosoughi
Journal:  BMC Musculoskelet Disord       Date:  2021-02-17       Impact factor: 2.362

6.  Management of developmental dysplasia of the hip in less than 24 months old children.

Authors:  Mehmet Bulut; Murat Gürger; Oktay Belhan; Omer Cihan Batur; Suat Celik; Lokman Karakurt
Journal:  Indian J Orthop       Date:  2013-11       Impact factor: 1.251

7.  Single-stage medial open reduction and Pemberton acetabuloplasty in developmental dysplasia of the hip.

Authors:  Mehmet Emre Baki; Celal Baki; Hafiz Aydin; Bünyamin Ari; Murat Özcan
Journal:  J Pediatr Orthop B       Date:  2016-11       Impact factor: 1.041

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.